References
- 1. Jarkowski A, Forrest A, Sweeney RP et al. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population. J Oncol Pharm Pract. 2012;18(1):91-6.
- 2. Marsot A, Boulamery A, Bruguerolle B et al. Vancomycin: A Review of Population Pharmacokinetic Analyses. Clin Pharmacokinet. 2012;51(1):1-13.
- 3. Adane ED, Herald M, Koura F. Pharmacokinetics of Vancomycin in Extremely Obese Patients with Suspected or Confirmed Staphylococcus aureus Infections. Pharmacotherapy. 2015;35(2):127-39.
- 4. Rodvold KA, Blum RA, Fischer JH et al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother. 1988;6:848-52.
- 5. Darko W, Medicis JJ, Smith A et al. Mississippi Mud No More: Cost-Effectiveness of Pharmacokinetic Dosage Adjustment of Vancomycin to Prevent Nephrotoxicity. Pharmacotherapy. 2003;23(5):643-50.
- 6. Lodise TP, Patel N, Lomaestro BM et al. Relationship between Initial Vancomycin Concentration-Time Profile and Nephrotoxicity among Hospitalized Patients. Clin Infect Dis. 2009;49(4):507-14.
- 7. De Hoog M, Mouton JW, Van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med. 2005;10:185-94.
- 8. Purwonugroho TA, Chulavatnatol S, Preechagoon Y et al. Population Pharmacokinetics of Vancomycin in Thai Patients. Scientific World Journal. 2012;2012:762649.
- 9. Lin WW, Wu W, Jiao Z et al. Population pharmacokinetics of vancomycin in adult Chinese patients with post-craniotomy meningitis and its application in individualised dosage regimens. Eur J Clin Pharmacol. 2016;72(1):29-37.
- 10. Stockmann C, Hersh AL, Roberts JK et al. Predictive Performance of a Vancomycin Population Pharmacokinetic Model in Neonates. Infect Dis Ther. 2015;4(2):187-98.
- 11. Hahn A, Frenck RW Jr, Zou Y et al. Validation of a pediatric population pharmacokinetic model for vancomycin. Ther Drug Monit. 2015;37(3):413-6.
- 12. Beal SL, Boeckmann AJ, Sheiner LB. NONMEM users guide. Parts I–VIII ICON Development Solutions.
- 13. Jamsen KM, McLeay SC, Barras MA, et al. Reporting a population pharmacokineticpharmacodynamic study: a journal's perspective. Clin Pharmacokinet. 2014;53(2):111-2.
- 14. Bakke V, Sporsem H, Von der Lippe E et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study.Acta Anaesthesiol Scand. 2017;61(6): 627-35.
- 15. Campassi ML, Gonzalez MC, Masevicius FD et al. Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment. Rev Bras Ter Intensiva. 2014; 26:13-20.
- 16. Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49: 325–7.
- 17. Saugel B, Gramm C, Wagner JY et al. Evaluation of a dosing regimen for continuous vancomycin infusion in critically ill patients: an observational study in intensive care unit patients. J Crit Care. 2014; 29:351-5.
- 18. Hutschala D, Kinstner C, Skhirdladze K et al. Influence of Vancomycin on Renal Function in Critically Ill Patients after Cardiac Surgery: Continuous versus Intermittent Infusion. Anesthesiology. 2009;111(2): 356-65.
- 19. Bamgbola O. Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab. 2016;7(3):136-47.
- 20. Nakamura T, Hashimoto Y, Kokuryo T et al. Effects of fosfomycin and imipenem/cilastatin on nephrotoxicity and renal excretion of vancomycin in rats. Pharmaceutical research.1998;15(5):734-8.
- 21. Philadelphia, PA: Pfizer; 2012. Zosyn (piperacillin-tazobactam) package insert. https://www.pfizermedicalinformation.com/en-us/zosyn/storage-handling.
- 22. Hammond DA, Smith MN, Li C, et al. Systematic Review and Meta-Analysis of Acute Kidney Injury Associated with Concomitant Vancomycin and Piperacillin/tazobactam. Clin Infect Dis. 2017;64 (5):666-74.
- 23. Blevins AM, Lashinsky JN, McCammon C et al. Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin/Tazobactam, Cefepime, or Merope nem. Antimicrob Agents Chemother. 2019. pii:AAC.02658-18.
- 24. Kim T, Kandiah S, Patel M et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC research notes. 2015;8(1):579.
- 25. Medellín-Garibay SE, Ortiz-Martín B, Rueda-Naharro A et al. Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. J Antimicrob Chemother. 2016;71(2):471-9.
- 26. Sanchez JL, Dominguez AR, Lane JR et al. Population pharmacokinetics of vancomycin in adult and geriatric patients: Comparison of eleven approaches. Int J Clin Pharmacol Ther. 2010;48: 525–33.
- 27. Garaud JJ, Regnier B, Ingleber F et al. Vancomycin pharmacokinetics in critically ill patients. J Antimicrob Chemother. 1984;14, Suppl. D, 53-5.
- 28. Rotschafer JC, Crossley K, Zaske DE et al. Pharmacokinetics of Vancomycin: Observations in 28 Patients and Dosage Recommendations. Antimicrob Agents Chemother. 1982;22(3):391-4.
- 29. Al-Kofide H, Zaghloul I, Al-Naim L Pharmacokinetics of vancomycin in adult cancer patients. J Oncol Pharm Pract. 2010;16(4):245-50.
- 30. Moore JN, Healy JR, Thoma BN et al. A Population Pharmacokinetic Model for Vancomycin in Adult Patients Receiving Extracorporeal Membrane. CPT Pharmacometrics Syst Pharmacol. 2016;5(9): 495-502.